1. Pink Sheet
  2. >>Geography

Pfizer & MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid

Tiered Pricing To Allow Equitable Access

 
• By Ian Schofield

An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it’s necessarily a good deal for lower-income countries.

License deals can help improve access to COVID-19 products across the world • Source: Alamy

In a move intended to maximize access to what has been described as a potential “game-changer” COVID-19 therapy, Pfizer Inc. has signed a deal with the Medicines Patent Pool for the voluntary licensing of its candidate oral antiviral, Paxlovid (PF-007321332, in combination with ritonavir).

The agreement covers 95 countries representing about 53% of the world’s population, including all low- and lower-middle-income countries as well...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.